Mary T. Obermeier

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 628 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

Mary T. Obermeier, Ming Yao, Ashish Khanna et al. · Drug Metabolism and Disposition · 2009 · 181 citations

Medicine, Pharmacokinetics, Pharmacology +17

Effects of bioflavonoids on hepatic P450 activities

Mary T. Obermeier, Randy White, Chung S. Yang · Xenobiotica · 1995 · 147 citations

Medicine, Medicinal Chemistry, Pharmacology +15

Discovery of 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

Scott H. Watterson, George V. De Lucca, Qing Shi et al. · Journal of Medicinal Chemistry · 2016 · 146 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Drug safety is a barrier to the discovery and development of new androgen receptor antagonists

William R. Foster, Bruce D. Car, Hong Shi et al. · The Prostate · 2010 · 119 citations

Medicine, Oncology, Pharmacology +15